Immunohistochemical profiling of liver metastases and matched-pair analysis in patients with metastatic pancreatic ductal adenocarcinoma.
Pancreatology
; 19(7): 963-970, 2019 Oct.
Article
en En
| MEDLINE
| ID: mdl-31542399
ABSTRACT
BACKGROUND:
The purpose of the current study was to investigate the immunohistochemical (IHC) profile of liver metastases (LM) in patients with pancreatic ductal adenocarcinoma (PDAC).METHODS:
Expression of 15 IHC markers in liver biopsies from 77 patients with PDAC, who were diagnosed between 2010 and 2014, were evaluated. In a separate subgroup analysis (nâ¯=â¯12), paired samples (LM and primary tumor) from the same patient were investigated for IHC profile differences.RESULTS:
LM samples were classified as pancreatobiliary-type (PB-type) in 72 patients (93.5%), intestinal-type (INT-type) in four patients (5.2%), and squamous in one patient (1.3%). There was no significant difference in overall survival (OS) between LM of the PB-type or INT-type (pâ¯=â¯0.097). In a multivariate analysis, age <70 years (pâ¯=â¯0.047), absence of SMAD4 mutation (pâ¯=â¯0.026), absence of CDX2 expression (pâ¯=â¯0.003), and well to moderate differentiation were significant prognostic factors for better OS in patients with LM (pâ¯=â¯0.031). Analysis of paired tissue samples from LM and the primary tumor revealed a difference in CDX2 (50% increase, pâ¯=â¯0.125) and SMAD4 (33% loss of SMAD4, pâ¯=â¯0.375).CONCLUSIONS:
CDX2 expression and SMAD4 mutation indicate a poor outcome in patients with LM of PDAC. Matched-pair analysis revealed differences in distinct IHC marker expression.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Neoplasias Pancreáticas
/
Adenocarcinoma
/
Regulación Neoplásica de la Expresión Génica
/
Neoplasias Hepáticas
Tipo de estudio:
Prognostic_studies
Límite:
Aged
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Pancreatology
Asunto de la revista:
ENDOCRINOLOGIA
/
GASTROENTEROLOGIA
Año:
2019
Tipo del documento:
Article